Journal
CURRENT ONCOLOGY REPORTS
Volume 14, Issue 1, Pages 79-84Publisher
SPRINGER
DOI: 10.1007/s11912-011-0201-0
Keywords
Brain metastases; Whole brain radiotherapy; Radiosurgery; Neuro-oncology
Categories
Funding
- Japan Society for the Promotion of Science [21591602]
- Grants-in-Aid for Scientific Research [21591602] Funding Source: KAKEN
Ask authors/readers for more resources
The goals of treatment for brain metastases (BMs) include preservation of function and improvement of survival. Although whole brain radiotherapy (WBRT) has been a mainstay in the treatment of BMs, stereotactic radiosurgery (SRS) monotherapy has been increasingly used because of concern about the deterioration of neurocognitive function as a late adverse effect of WBRT. The results of four randomized controlled trials comparing focal treatment alone versus focal treatment combined with WBRT have shown, however, that SRS monotherapy significantly increases the risk of brain tumor recurrence (BTR) and that this increased risk of BTR may cause deterioration of neurocognitive function. We suggest identifying patients according to their risk of BTR when selecting treatment. Patients who have solitary BM with the absence of extracranial metastases may be indicated for SRS monotherapy given the lower risk of BTR compared with those having multiple BMs or extracranial metastases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available